

## Inventiva to Participate in Upcoming September Investor Conferences

**Daix (France), New York City (New York, United States), September 4, 2025** – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events:

### **H.C. Wainwright 27th Annual Global Investment Conference**

**Date:** Tuesday, September 9, 2025

**Time of the fireside chat:** 3:00pm (EDT)/9:00pm (CEST)

**Location:** New York, NY

### **8th Edition of the Lyon Pôle Bourse Forum**

**Date:** Tuesday, September 23, 2025

**Location:** Lyon, France

### **KBC Life Sciences Conference**

**Date:** Thursday, September 25, 2025

**Time of the presentation:** 5:00am (EDT)/11:00am (CEST)

**Location:** Brussels, Belgium

### **Stifel 2025 Virtual Cardiometabolic Forum**

**Date:** Tuesday, September 30, 2025

**Time of the presentation:** 9:30am (EDT)/3:30pm (CEST)

**Location:** Virtual

### **European MIDCAP Event 2025**

**Date:** Tuesday, September 30 - Wednesday, October 1, 2025

**Location:** Paris, France

### **About Inventiva**

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiv3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). <http://www.inventivapharma.com>

## Contacts

### **Inventiva**

Pascaline Clerc  
EVP, Strategy and Corporate Affairs  
[media@inventivapharma.com](mailto:media@inventivapharma.com)  
+1 202 499 8937

### **ICR Healthcare**

Alexis Feinberg  
Media Relations  
[inventivapr@icrhealthcare.com](mailto:inventivapr@icrhealthcare.com)  
+1 203 939 2225

### **ICR Healthcare**

Patricia L. Bank  
Investor Relations  
[patti.bank@icrhealthcare.com](mailto:patti.bank@icrhealthcare.com)  
+1 415 513 1284